AbbVie Downplays Impact Of Viekira Pak Safety Issues
This article was originally published in The Pink Sheet Daily
Executive Summary
Because Child-Pugh B cirrhotic patients are such a small portion of hepatitis C population, AbbVie predicts labeling update won't make a material difference in sales; outreach to clinicians and health plans is going well, CEO Gonzalez adds.